Novo Nordisk heads into this earnings reaction as a stock that has cooled off in the short term, with the share price down about 13% over the past week and 8% over the past month, even as many investors still view it as a long term growth engine in weight loss and diabetes. The Q2 headline is simple: solid demand for obesity and diabetes drugs translated into DKK 78,488m of revenue, yet profit was squeezed, with gross margin falling to 78.2% and net income at DKK 20,989m.
Is Novo Nordisk trading at a rare bargain on an 11.2x P/E and a DKK294.3 price against a DKK863.54 DCF estimate, or are earnings quality flags doing the real work here? Compare that story against the full valuation analysis for Novo Nordisk
Q2 2026 Earnings Summary
- Revenue (Q2 2026 vs Q2 2025): DKK 78,488m vs DKK 76,857m (up 2.1%)
- Net Income (Excl. Extra Items, Q2 2026 vs Q2 2025): DKK 20,989m vs DKK 26,503m (down 20.8%)
- Basic EPS (Q2 2026 vs Q2 2025): DKK 4.74 vs DKK 5.96 (down 20.5%)
- Gross Margin (Q2 2026 vs Q2 2025): 78.2% vs 82.7% (margin compression of 4.5 percentage points)
Prefer clean visuals instead of scrolling through pages of earnings tables and margin figures? Get a full chart-based view of Novo Nordisk that highlights its valuation picture in an easy snapshot via our company report for Novo Nordisk.
Novo Nordisk’s Growth Story Hinges On Wegovy Pill Execution
The bullish story on Novo Nordisk is that GLP‑1 obesity and diabetes drugs can keep delivering strong volume growth as access widens and new formats launch globally. Q2 gives concrete milestones on that front. Oral Wegovy now has about 1.5m patients and roughly 5m U.S. prescriptions, with around 90% share of the oral obesity drug segment and about 60% new‑to‑brand prescription share. That shows the pill format is reaching untreated patients rather than just shifting existing injectable users.
Outside the U.S., early rollouts back this up. In the U.K., around 300,000 patients started treatment within weeks, and Novo Nordisk obesity share in sell in moved from about 30% to about 45%. The UAE already accounts for roughly half of the oral segment. These are the kind of access and penetration milestones the growth thesis relies on, even as pricing and margin pressure hold back earnings growth.
Reveal where the surface looks calm, but the multi year models for Novo Nordisk start to diverge and where the consensus might quietly be bracing for the next earnings inflection. Access the full revenue, margin and EPS timeline in the analyst estimates for Novo Nordisk.Novo Nordisk bears find fresh support on margins and pipeline
The bearish line on Novo Nordisk is that a concentrated GLP‑1 obesity and diabetes portfolio, rising pricing pressure and heavy investment needs will squeeze margins and expose execution risk. Q2 margins move this concern from theory to evidence. Gross margin dropped to 78.2%, with lower realized prices and a DKK 3b manufacturing rightsizing cost biting into profitability even as demand stayed strong. Injectable Wegovy in the U.S. saw volumes grow while sales fell due to weaker pricing and a deliberate push into self pay, which fits the fear that volume now comes with thinner economics.
Pipeline events also lean the bearish way. The ZEUS miss for ziltivekimab and the CagriSema failure weaken the diversification story beyond GLP‑1. Combined with early generic semaglutide entries and ongoing cyber and legal overhangs, this quarter does not disprove the bear case. It shows several of its key milestones are starting to appear in the numbers.
Review whether Novo Nordisk’s margin pressure, debt load and non cash earnings are early warning signs. Expose the full risk analysis for Novo Nordisk which shows 3 important warning signsStay Ahead With Simply Wall St
If the mix of strong Novo Nordisk demand figures and tighter margins has your attention, register for free with Simply Wall St and add the stock to a Watchlist so you can track its share price against fair value and watch for a setup that fits your plan. Once you decide to take a position, use the Portfolio Command Center to cut through market noise and get focused updates on the metrics that matter most to you. For a longer term view, tap into the Community to see how other investors are thinking about catalysts, risks and expectations. This way you can spot potential turning points early and stay a step ahead of the broader market.
Seeking Alternatives Beyond Novo Nordisk?
Fresh ideas do not stay under the radar for long. Spot potential breakouts and fading laggards while it still matters, before the crowd catches up. Get in early.
- Scan for potential cash rich compounders by reviewing a curated list of solid balance sheet and fundamentals stocks (420 results). Use it to spot balance sheet strength before momentum traders start piling in.
- Ride powerful AI momentum with companies already turning code into cash by assessing 67 profitable AI stocks that aren't just burning cash. Do not wait until every headline chases the same tickers.
- Target resilient income ideas while yields remain elevated through a hand picked 444 dividend fortresses. Identify potential income candidates before payout stories get fully priced in.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com